STOCK TITAN

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Agios Pharmaceuticals will present new data on their PK activators mitapivat and tebapivat at the 66th ASH Annual Meeting in San Diego from December 7-10, 2024. Key highlights include results from the Phase 3 ENERGIZE-T study of mitapivat in transfusion-dependent thalassemia, Phase 1 data on tebapivat in sickle cell disease, and a Phase 2b trial update in myelodysplastic syndromes.

The presentations will feature 16 abstracts led by Agios and external collaborators, including oral presentations on thalassemia research and poster presentations on sickle cell disease treatments. The company will host a live investor event with leadership and medical experts on December 9.

Agios Pharmaceuticals presenterà nuovi dati sui loro attivatori PK mitapivat e tebapivat al 66° Congresso Annuale ASH a San Diego dal 7 al 10 dicembre 2024. I punti salienti includono i risultati dello studio di fase 3 ENERGIZE-T su mitapivat nella talassemia da trasfusione, i dati di fase 1 su tebapivat nella malattia delle cellule falciformi, e un aggiornamento sulla sperimentazione di fase 2b nei sindromi mielodisplastiche.

Le presentazioni includeranno 16 abstract guidati da Agios e collaboratori esterni, comprese presentazioni orali sulla ricerca sulla talassemia e presentazioni poster sui trattamenti per la malattia delle cellule falciformi. L'azienda ospiterà un evento dal vivo per gli investitori con leader e esperti medici il 9 dicembre.

Agios Pharmaceuticals presentará nuevos datos sobre sus activadores PK mitapivat y tebapivat en el 66º Congreso Anual de ASH en San Diego del 7 al 10 de diciembre de 2024. Los aspectos más destacados incluyen los resultados del estudio de fase 3 ENERGIZE-T de mitapivat en talasemia dependiente de transfusiones, datos de fase 1 sobre tebapivat en enfermedad de células falciformes, y una actualización de ensayo de fase 2b en síndromes mielodisplásicos.

Las presentaciones incluirán 16 resúmenes liderados por Agios y colaboradores externos, incluyendo presentaciones orales sobre investigación en talasemia y presentaciones en cartel sobre tratamientos para la enfermedad de células falciformes. La empresa organizará un evento en vivo para inversores con líderes y expertos médicos el 9 de diciembre.

Agios Pharmaceuticals는 2024년 12월 7일부터 10일까지 샌디에고에서 열리는 제66회 ASH 연례 회의에서 PK 활성제인 mitapivattebapivat에 대한 새로운 데이터를 발표할 예정입니다. 주요 내용으로는 수혈 의존성 갈혈증에서의 mitapivat에 대한 3상 ENERGIZE-T 연구 결과, 겸상세포질병에서의 tebapivat에 대한 1상 데이터, 그리고 골수형성이상증후군에 대한 2b상 시험 업데이트가 포함됩니다.

발표는 Agios와 외부 협력자가 주도하는 16개의 초록으로 구성되며, 갈혈증 연구에 대한 구두 발표와 겸상세포질병 치료에 대한 포스터 발표가 포함됩니다. 회사는 12월 9일 리더십과 의학 전문가와 함께하는 실시간 투자자 행사를 개최할 것입니다.

Agios Pharmaceuticals présentera de nouvelles données sur ses activateurs PK mitapivat et tebapivat lors de la 66e Réunion Annuelle ASH à San Diego du 7 au 10 décembre 2024. Les points forts incluent les résultats de l'étude de phase 3 ENERGIZE-T sur mitapivat dans la thalassémie dépendante des transfusions, des données de phase 1 sur tebapivat dans la maladie de cellules falciformes, et une mise à jour d'un essai de phase 2b dans les syndromes myélodysplasiques.

Les présentations comprendront 16 résumés dirigés par Agios et des collaborateurs externes, y compris des présentations orales sur la recherche sur la thalassémie et des présentations d'affiches sur les traitements de la maladie de cellules falciformes. L'entreprise organisera un événement en direct pour les investisseurs avec des dirigeants et des experts médicaux le 9 décembre.

Agios Pharmaceuticals wird neue Daten zu ihren PK-Aktivatoren mitapivat und tebapivat auf dem 66. ASH Jahresmeeting in San Diego vom 7. bis 10. Dezember 2024 präsentieren. Zu den wichtigsten Punkten gehören Ergebnisse der Phase-3-Studie ENERGIZE-T zu mitapivat bei transfusionsabhängiger Thalassämie, Phase-1-Daten zu tebapivat bei Sichelzellenanämie sowie ein Update zur Phase-2b-Studie bei myelodysplastischen Syndromen.

Die Präsentationen umfassen 16 Abstracts, die von Agios und externen Kollegen geleitet werden, einschließlich mündlicher Präsentationen zur Thalassämieforschung und Posterpräsentationen zu Behandlungen für Sichelzellenanämie. Das Unternehmen wird am 9. Dezember eine Live-Veranstaltung für Investoren mit Führungskräften und medizinischen Experten ausrichten.

Positive
  • None.
Negative
  • None.

– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –

– Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published –

– Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 –

CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on mitapivat and tebapivat (AG-946), the company’s PK activators, will be featured in oral and poster presentations during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 7-10, 2024.

“These data we are presenting at ASH reaffirm our confidence in our growing pipeline focused on improving red blood cell health,” Sarah Gheuens, M.D., Ph.D., chief medical officer and head of R&D at Agios. “We will highlight the clinical progress of our two PK activators – mitapivat and tebapivat – in multiple rare blood disorders with high patient needs, including thalassemia, sickle cell disease and myelodysplastic syndromes. These advancements showcase the quality of science and potential novel solutions coming out of our research and development efforts.”

Key presentations and publications at ASH 2024 will include:

  • An oral presentation on results from the Phase 3 ENERGIZE-T study evaluating mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia versus placebo. Alongside the positive results from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent alpha- or beta-thalassemia previously presented at the 2024 European Hematology Association (EHA) Congress, these data support mitapivat’s potential as an oral, disease-modifying therapy across the full range of patients with thalassemia regardless of transfusion status.
  • A poster presentation of a Phase 1 study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of tebapivat in patients with sickle cell disease, providing further evidence that PK activation may have beneficial effects in this patient population.
  • A trial-in-progress publication that outlines the Phase 2b study evaluating the efficacy and safety of tebapivat in patients with anemia due to lower-risk myelodysplastic syndromes.

In total, 16 presentations and publications led by Agios and external collaborators will be shared at ASH 2024.

ASH 2024 Accepted Abstracts

Title NumberDate/TimePresenterAcceptance
Thalassemia
ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia409Sunday, December 8, 2024; 9:30 AM PTMaria Domenica Cappellini, M.D., University of Milan, ItalyOral
PKM2 binds to the regulatory regions of Gata-1 and STAT5 in β-thalassemic mouse erythroblasts410Sunday, December 8, 2024; 9:45 AM PTEnrica Federti, Ph.D., University of Verona, Verona, ItalyOral
Ex vivo treatment by mitapivat, an allosteric pyruvate kinase activator, reduced hemolysis and reactive oxygen species in red blood cells of non-regularly transfused hemolytic anemic patients with β-thalassemia/Hb E disease2479Sunday, December 8, 2024; 6:00 – 8:00 PM PTThidarat Suksangpleng, Ph.D., Siriraj Hospital, Mahidol University, Bangkok, Thailand

Poster
Thalassemia scenario in Brazil: A descriptive study2310Saturday, December 7, 2024; 5:30 – 7:30 PM PTCatherine Moura, M.D., MSc, Abrasta – Brazilian Thalassemia Association, São Paulo, SP, BrazilPoster
Understanding Health Literacy Among Patients With Thalassemia: A Global Patient Survey by the Thalassemia Advocacy Advisory Council Blood Nov. 2024 supplementary issueN/ASujit Sheth, M.D., Weill Cornell Medicine, New York City, New York

Publication
Molecular characterization of HbH in Spain

Blood Nov. 2024 supplementary issueN/AAna María Villegas, M.D., University Hospital Clínico San Carlos, Complutense University of Madrid, Madrid SpainPublication
Molecular characterization of NTDT in SpainBlood Nov. 2024 supplementary issueN/AAna María Villegas, M.D., University Hospital Clínico San Carlos, Complutense University of Madrid, Madrid SpainPublication
Molecular characterization of TDT in Spain2024 supplementary issueN/AAna María Villegas, M.D., University Hospital Clínico San Carlos, Complutense University of Madrid, Madrid SpainPublication
Sickle Cell Disease
Results From A Phase 1 Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Tebapivat (AG-946) In Patients With Sickle Cell Disease2496Sunday, December 8, 2024; 6:00 – 8:00 PM PT

Julia Xu, M.D., MScGH, Vascular Medical Institute, University of Pittsburgh, Pittsburg, PAPoster
Dual Activation of PKR and PKM2 Reduced the Development of Fibrosis and Iron Deposition in a Sickle Cell Disease Nephropathy Mouse Model1107Saturday, December 7, 2024; 5:30 – 7:00 PM PTTrang Nguyen, ScB, Agios Pharmaceuticals, Inc., Cambridge, MAPoster
Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease are Sustained During Extended Therapy2491Sunday, December 8, 2024; 6:00 – 8:00 PM PTXunde Wang, Ph.D., National Institute of Health, Bethesda, MDPoster
Myelodysplastic Syndromes
A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes Blood Nov. 2024 supplementary issueN/AAmer M Zeidan, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, CTPublication
Pyruvate Kinase Deficiency
Clinical Monitoring Practices Among Adult Patients with Pyruvate Kinase Deficiency Who Have Never Been Transfused 3696Sunday, December 8, 2024; 6:00 – 8:00 PM PTStefan W. Eber, M.D., Ph.D., M1 Private Clinic Munich, Munich, GermanyPoster
Other
uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis794Monday, December 9, 2024; 10:45 AM PTMar Manu Pereira, Ph.D., Vall d’Hebron Barcelona Hospital, Barcelona, SpainOral
PIEZO1 gain-of-function variants lead to alterations in late-stage erythropoiesis by enhancing enucleation rate 3837Monday, December 9, 2024; 6:00 – 8:00 PM PT

Barbara Eleni Rosato, Ph.D., University of Naples Federico II, Naples, ItalyPoster
A Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II – Results from the 8-Week Dose-Escalation Period3831Monday, December 9, 2024; 6:00 – 8:00 PM PTThomas Doeven, M.D., Center for Benign Hematology, Thrombosis and Hemostasis – Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, NetherlandsPoster

Please refer to the ASH 2024 online program for full session details and data presentation listings and visit the Agios booth (#105) onsite.

Investor Event at ASH 2024
Agios will host a live and webcast investor event with the company's leadership team and medical experts. The event will take place on Monday, December 9, in San Diego, starting at 7:00 a.m. PT (10:00 a.m. ET). The webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. The archived webcast will be available on the company's website approximately two hours after the event.

About PYRUKYND® (mitapivat)
PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States, and for the treatment of PK deficiency in adult patients in the European Union.

IMPORTANT SAFETY INFORMATION
Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Adverse Reactions: Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

  • Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
  • Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
  • Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
  • Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
  • UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
  • P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see full Prescribing Information and Summary of Product Characteristics for PYRUKYND.

About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of PYRUKYND® (mitapivat) and tebapivat; Agios’ plans, strategies and expectations for its preclinical, clinical and commercial advancement of its drug development, including PYRUKYND® and tebapivat; Agios’ plans regarding future data presentations; and the potential benefits of Agios’ strategic plans and focus. The words “anticipate,” “expect,” “goal,” “hope,” “milestone,” “plan,” “potential,” “possible,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of TMPRSS6 siRNA, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios’ cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com


FAQ

What are the key studies Agios (AGIO) is presenting at ASH 2024?

Agios is presenting the Phase 3 ENERGIZE-T study results for mitapivat in transfusion-dependent thalassemia, Phase 1 data on tebapivat in sickle cell disease, and Phase 2b trial updates in lower-risk myelodysplastic syndromes at ASH 2024.

When and where is Agios (AGIO) hosting their investor event at ASH 2024?

Agios is hosting a live and webcast investor event on Monday, December 9, 2024, at 7:00 a.m. PT (10:00 a.m. ET) in San Diego.

How many presentations will Agios (AGIO) feature at ASH 2024?

Agios and external collaborators will share a total of 16 presentations and publications at ASH 2024, including oral presentations, poster presentations, and publications.

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

AGIO Rankings

AGIO Latest News

AGIO Stock Data

3.20B
56.77M
1.55%
103.19%
7.22%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE